Introduction {#s1}
============

Mucosa-associated lymphoid tissue lymphoma (MALT lymphoma) accounts for 8% of B-cell lymphomas according to the recent WHO classification.[@R1] Initially described as gastric lymphoma by British pathologists Peter Isaacson and Dennis Wright in 1984, the debate whether this disease was in fact a lymphoma rather than a more 'sophisticated gastritis' ended only in 1994 after a decade of heated discussion, when 'extranodal marginal zone B-cell lymphoma of the MALT' was finally included in the Revised European American Lymphoma Classification. The work of Peter Isaacson has thus both defined a distinct lymphoma entity, but in the following years laid the foundation for defining the underlying cause as well as developing individualised therapy for *HP*-associated gastric MALT lymphoma---a feat that is in fact unrivalled in modern oncology. While the stomach is still the most common localisation documented in up to 30%--50% of cases, a shift towards more extragastric manifestations including ocular adnexa, lung, thyroid and parotid glands is apparent.[@R2] MALT lymphoma is a lymphoid B-cell malignancy highly depended on microenvironmental factors, exemplified by the association of gastric MALT lymphoma with *HP*. Autoimmune disorders (AD), for example, Sjogren's syndrome and chronic autoimmune thyroiditis Hashimoto are also associated with the development of MALT lymphoma. According to current concepts, both *HP*-gastritis and AD trigger lymphomagenesis via a multistep process of perpetual (auto-)antigenic stimulation of marginal zone B-cells and activation of the NF-Kappa B pathway.

The paradigm of antibiotic treatment for MALT lymphoma {#s2}
======================================================

Shoot on sight---*HP*-eradication {#s2-1}
---------------------------------

*HP*-associated gastritis was initially defined as the leading cause of gastric MALT lymphoma demonstrated in up to 90%--95%.[@R2] The bacteria, however, are not always histologically detectable and diagnostics may be completed with stool antigen or breath test and eventually serology for *HP*-specific IgG. According to current guidelines, a single course of antibiotics is the standard for upfront treatment of *HP*-positive gastric MALT lymphomas resulting in long-term remissions in 70%--80% of patients, and complete remissions (CR) in up to 60%.[@R3] *HP*-eradication is currently our treatment of choice irrespective of the stage of gastric lymphoma.[@R2] Choice of antibiotics should be matched to local resistance patterns, but usually includes at least two antibiotics for 7--14 days in combination with a proton pump inhibitor. In spite of emerging rates of resistance to clarithromycin, the macrolide (plus either amoxicillin or metronidazole) is still an option due to additional immunomodulatory and antilymphoma effects. Response to eradication is assessed by re-endoscopy 3--6 months after treatment and should always include gastric mapping biopsies and assessment of specimens by an experienced hematopathologist according the GELA response criteria. However, as MALT lymphoma is a malignancy in slow-motion, time to best response may vary between weeks up to 2 years. This is underlined by a series of 108 stage IE patients with residual MALT lymphoma at 12 months after eradication, of whom 32% further improved to CR without further therapy.[@R5] In line with current guidelines, we recommend no further treatment in patients with successful *HP*-eradication and residual disease in the absence of progression.

A point controversially discussed is the value of eradication in gastric MALT lymphoma with *HP*-negativity or disseminated disease. Response to *HP*-eradication has been reported in series also from our institution in patients with *HP*-negative or disseminated gastric MALT lymphoma including stage IV patients with bone marrow infiltration.[@R2] While the exact reason remains somewhat elusive, it might again be related to direct immunomodulatory effects of macrolides, and current data and guidelines suggest *HP*-eradication as safe for these cohorts in absence of a high symptomatic burden.[@R3]

Antibacterial eradication for extragastric MALT lymphoma {#s2-2}
--------------------------------------------------------

In ocular adnexal MALT lymphoma (OAML), *Chlamydophila psittaci* (*CP*) has been suggested as a potential trigger,[@R6] and a phase II trial showed efficacy of doxycycline 200 mg for 3 weeks in 27 patients. Patients tested positive for *CP*-DNA had better results than negative patients (64% vs 38%, p=0.25). Strong geographic differences in *CP*-prevalence of OAML patients have been reported since, and in fact in our own collective of 60 patients none tested *CP*-positive. In addition, further series reported no response to doxycycline irrespective of *CP*-status, therefore we do not apply doxycycline for *CP*-eradication in OAML. Further pathogens associated with MALT lymphoma include *Borrelia burgdorferi* for MALT lymphoma of the skin, *Achromobacter xylosoxidans* for pulmonary MALT lymphoma and *HP* for various extragastric sites, but no consistent data on efficacy of eradication are available and eradication cannot generally be recommended.

Systemic treatment of MALT lymphoma {#s3}
===================================

Chemotherapy-based therapy {#s3-1}
--------------------------

Chemotherapy-based treatment evaluated for MALT lymphoma include various types of combination regimens adapted from other indolent B-cell lymphomas, including chlorambucil±rituximab (R) and R-bendamustine with both regimens resulting in overall response rates (ORR) \>90%.[@R7] Chlorambucil was evaluated with great efforts in the largest randomised trial for MALT lymphoma, the IELSG-19 study, based on a three-arm protocol comparing chlorambucil (6 weeks continuously followed by 16 weeks intermittent intake)±R versus R-monotherapy.[@R7] Final long-term results after a median follow-up of \>7 years reported a significantly better 5-year EFS for R-chlorambucil versus chlorambucil (68% vs 51%; HR: 0.54, 95% CI: 0.38 to 0.77) and also initial ORR was higher for the combination arm (95% vs 86%). No favour in terms of overall survival (OS), however, was seen. Based on these data, R-chlorambucil is regarded as standard therapy as it has been tested in a randomised study---even though the ORR in the phase II setting are lower than for other agents, suggesting that it might not have been the optimal choice as test arm over two relatively ineffective monosubstances. In addition, long-term administration of chlorambucil is highly dependent on patient-compliance. R-bendamustine is a regimen commonly used in indolent lymphoma, with activity and safety proven in large randomised phase III trials for mixed collectives of lymphoma entities. For MALT lymphoma, a Spanish phase II trial reported an ORR of 100% in 60 patients, with comparable long-term results to the IELSG-study (EFS 87.7% at 7 years, 95% CI: 76 to 94), with a step-down protocol allowing a treatment stop after cycle 4 in case of CR and only patients with response but residual disease continued for a total of six cycles.[@R8] In addition, the onset of responses is relatively quick, which in addition to the shorter overall duration makes R-Benda our current therapy of choice for patients requiring therapy, that is, symptomatic disease. Anthracycline-based therapy should be reserved for patients with transformation to aggressive lymphoma. Finally, current data in MALT lymphoma are not supporting maintenance treatment following R-chemo.

Targeting CD20 {#s3-2}
--------------

Several small phase II trials including patients with gastric and extragastric disease, as well as the control arm of the IELSG-19 trial provided sufficient evidence for use of single agent rituximab in routine practice.[@R7] Response rates range between 60%--80% and whereas long-term outcome appears slightly inferior in terms of relapse rates (but not OS) compared with chemotherapy, we consider R-monotherapy feasible and particularly suitable for frail patients or patients with symptomatic disease but low tumour burden. A four-time-weekly schedule of 375 mg/m^2^ is commonly being used in our practice with the potential for retreatment in case of relapse, while in the IELSG-19 trial, a prolonged treatment of 6 months was applied.[@R7]

In addition to R, also 'next generation' anti-CD20 antibodies have been used for treatment of MALT lymphoma. In small series, both ofatumumab and obinutuzumab have been applied in patients with marginal zone lymphoma, and have shown low toxicity along with clinically meaningful responses.[@R10] No trial in MALT lymphoma patients only has been published for obinutuzumab, but its use and efficacy have been shown in a wider population of patients with marginal zone lymphoma.[@R10] In the O-MA1 trial, ofatumumab showed an ORR of 81% with a CR rate of 50% in 16 patients with MALT lymphoma.[@R11] Those next generation compounds might be of interest for further studies to potentially overcome resistance to R-monotherapy and also for combination regimens.

An attractive but unfortunately rarely used treatment strategy is radio-immunotherapy with 90Y-ibritumumab-tiuxetan, which showed high response rates in various CD20+ malignancies including series of heavily pretreated patients with MALT lymphoma.[@R12]

Immunomodulatory treatment for MALT lymphoma {#s3-3}
--------------------------------------------

In view of the dependency of MALT lymphoma cells on their microenvironment, immunomodulatory treatment appears reasonable and investigation of such concepts was an important focus at our centre in recent years. The immunomodulatory drug lenalidomide was investigated as monotherapy and in combination with R in *HP*-resistant or extragastric MALT lymphomas, and especially the combination showed high activity with an ORR of 80% reported in 46 patients.[@R13] Positive long-term results including additional delayed remissions have been reported after 5 years follow-up. Unfortunately, in the AUGMENT trial that led to approval of R-lenalidomide for relapsed follicular lymphoma, the small and underpowered subgroup of marginal zone lymphoma was negative, thus no approval is expected in the near future.[@R14] Nevertheless, the recent ESMO guidelines on MALT lymphoma have included R-lenalidomide for relapsed and refractory MALT lymphoma in their algorithm.[@R4] Currently, there are no data to justify the use of lenalidomide and R in the first-line treatment of MALT lymphoma, although promising results for application in 110 untreated indolent lymphomas (including a cohort of 30 patients with marginal zone lymphoma) have been published.[@R15] A long-term analysis of the marginal zone cohort only showed an ORR of 93% with 70% CR/Cru, and a median PFS of 59.8 months.[@R16] However, as with other studies of mixed marginal-zone lymphoma cohorts, only 11/30 patients had MALT lymphoma which does not allow for further distinct analysis. Toxicities of lenalidomide in MALT lymphoma (both as monotherapy as well as in combination) nevertheless appear mild, and constituted mostly rash and pruritus along with mild leukocytopenia and thrombocytopenia in the respective studies.

A further compound of interest in the context of immunomodulation is clarithromycin, which displays both antimicrobial effects and direct immunomodulatory and antiproliferative effects including inhibition of IL-6 and mTOR. Clarithromycin monotherapy was active in two phase II studies for relapsed or extragastric MALT lymphoma in the absence of active *HP*/*CP*-infection and showed response rates up to 50%, with the highest activity reported in OAML.[@R17] In addition, a recent retrospective analysis including 55 patients reported 2×500 mg daily for (3 to) 6 months as most feasible in terms of responses and side effects.[@R19] Based on the data reported so far and in view of the favourable toxicity profile, we use clarithromycin for antiproliferative treatment of MALT lymphoma patients with low tumour burden and particularly with OAML.

Targeted therapies {#s3-4}
------------------

Due to the role of the NF-kB pathway in the pathogenesis of MALT lymphoma, the proteasome inhibitor bortezomib was tested in two pilot studies at different dose levels (1.3 mg/m^2^ and 1.5 mg/m^2^, respectively).[@R9] A high activity was shown in both studies, with the ORR being up to 80%, but the rate of neurotoxicity was nevertheless substantial. In view of the increasing role of novel agents targeting BTK and Pi3K in various indolent lymphomas, their use in patients with MALT lymphoma might also be of interest. In fact, ibrutinib has been approved for therapy of relapsed/refractory marginal zone lymphoma due to the results of a phase II study, which also included 32 patients with MALT lymphoma.[@R20] In spite of the approval, both the median PFS of 13.8 months as well as the response rate of 50% appear slightly sobering, and are in fact (indirectly) comparable to application of clarithromycin, which---in our opinion---also has the advantage of a more favourable cost-profile and toxicity-profile.

Conclusion {#s4}
==========

*HP*-eradication is the standard of care in patients with gastric MALT lymphoma irrespective of stage. For patients with symptomatic disease and need for systemic treatment, R-bendamustine and R-monotherapy are currently the most commonly applied therapies outside of clinical trials, while for the less symptomatic patients, clarithromycin is a good alternative. Localised disease can also be treated with low-dose radiotherapy (eg, 2×2 Gy), which has excellent palliative outcome and can also be applied in patients with bilateral OAML.[@R21] See [figure 1](#F1){ref-type="fig"}. Finally, the indolent clinical course of MALT lymphoma is highlighted by an overall survival \>80% at 10 years.[@R2] In view of this, active surveillance constitutes an important option in the care of patients with MALT lymphoma.
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